The effect of antimalarial chloroquine therapy and prophylaxis on concurrent infection with Onchocerca volvulus in Ecuador.
The effect of chloroquine phosphate on Onchocerca volvulus in vivo was studied in Ecuadorians undergoing treatment for malaria. All persons with a diagnosis of acute malaria and treated with 2500 mg of chloroquine over 3 d showed a 100% reduction of dermal O. volvulus microfilariae 7 d after treatment. However, 28 d after treatment the microfilarial densities returned to their pre-treatment levels and at 35 d they had increased to 121.6% of their pre-treatment values. Treatment did not appear to have any effect on the adult O. volvulus examined histologically in extirpated nodules. Patients treated for acute malaria and subsequently kept on a prophylactic regimen of 500 mg chloroquine weekly showed a reduction of 56.7% from pre-treatment microfilarial density after 27 weeks. Patients who underwent nodulectomy as well as treatment for acute malaria and were given 500 mg of chloroquine prophylactically for 27 weeks showed a reduction in dermal microfilarial density of 93.6%. Symptoms of onchocerciasis were reduced in the latter group of patients, with the elimination of all acute dermatological changes within 6 weeks. Ocular examination of these surgically and chemotherapeutically treated individuals revealed reductions of 94.9% of microfilariae in the anterior chamber, 95.9% of live microfilariae in the cornea, and 95.1% of dead microfilariae in the cornea. There was a reduction of 69.8% in corneal fluffy opacities. No alteration in the visual acuity or in visible lesions in the posterior segment was recorded. The results suggest that a complex interaction between chloroquine and O. volvulus takes place in vivo, which can be beneficial to the patient over a long period.(ABSTRACT TRUNCATED AT 250 WORDS)
Guderian
R H
RH
Onchocerciasis Project, Community Development Vozandes, Hospital Vozandes, Quito, Ecuador.
Anselmi
M
M
Beck
B J
BJ
Mackenzie
C D
CD
Williams
J F
JF
Proaño
J R
JR
Cooper
P J
PJ
D000208:Acute Disease; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D002738:Chloroquine / Q000031:analogs & derivatives* / Q000494:pharmacology; D005123:Eye / Q000469:parasitology; D006801:Humans; D008288:Malaria / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009854:Onchocerca / Q000187:drug effects*; D009855:Onchocerciasis / Q000150:complications / Q000469:parasitology*; D015827:Onchocerciasis, Ocular / Q000469:parasitology; D012867:Skin / Q000469:parasitology
D000962:Antimalarials; C023676:chloroquine diphosphate; D002738:Chloroquine